Compass Therapeutics, Inc.
CMPX
Rank in Stocks
#17805
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing... Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
Share Price
$0.82
Last synced: 2026-11-12
Market Cap
$153.17M
Change (1 day)
-1.23%
Change (1 year)
-83.23%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Compass Therapeutics, Inc. (CMPX)
Category
Healthcare
Earnings for Compass Therapeutics, Inc. (CMPX)
Earnings in Sep 2026 TTM: $-86.36M
According to Compass Therapeutics, Inc.'s latest financial reports, its current earnings (TTM) are $-86.36M. In 2025 the company earned $-66.49M, a decrease compared to its 2024 earnings of $-49.38M. The earnings shown on this page are earnings before interest and taxes, or EBIT.
Earnings history for Compass Therapeutics, Inc. from 2019 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-86.36M | 29.88% |
| 2025 | $-66.49M | 34.66% |
| 2024 | $-49.38M | 16.19% |
| 2023 | $-42.49M | 8.33% |
| 2022 | $-39.23M | -52.27% |
| 2021 | $-82.18M | 178.88% |
| 2020 | $-29.47M | -22.82% |
| 2019 | $-38.18M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $-57.82M | -33.05% |
US
|
|
| $4.76B | -5,611.36% |
US
|
|
| $-2.73B | 3,060.10% |
US
|
|
| $-4.02B | 4,550.64% |
AU
|
|
| $2.79B | -3,334.63% |
BE
|
Questions about Compass Therapeutics, Inc.'s net income
What is Compass Therapeutics, Inc.'s net income?
Compass Therapeutics, Inc.'s net income over the last twelve months is $-86.36M, as of Sep 2026.
What was Compass Therapeutics, Inc.'s net income in 2025?
In 2025, Compass Therapeutics, Inc.'s net income was $-66.49M, compared with $-49.38M in 2024.
How has Compass Therapeutics, Inc.'s net income changed since 2020?
From 2020 to 2025, Compass Therapeutics, Inc.'s net income was highest in 2020 ($-29.47M) and lowest in 2021 ($-82.18M).
How does Compass Therapeutics, Inc.'s net income compare with similar companies?
Compass Therapeutics, Inc.'s net income ($-86.36M) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $4.76B.